SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Burzynski Research Institute Inc – ‘10-Q’ for 11/30/11 – ‘EX-101.INS’

On:  Tuesday, 1/17/12, at 1:46pm ET   ·   For:  11/30/11   ·   Accession #:  1104659-12-2343   ·   File #:  0-23425

Previous ‘10-Q’:  ‘10-Q’ on 10/17/11 for 8/31/11   ·   Next:  ‘10-Q’ on 7/16/12 for 5/31/12   ·   Latest:  ‘10-Q’ on 1/16/24 for 11/30/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/17/12  Burzynski Research Institute Inc  10-Q       11/30/11   22:1.1M                                   Toppan Merrill/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report Pursuant to Sections 13 or 15(D)   HTML    221K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     16K 
 3: EX-32.1     Certification -- §906 - SOA'02                      HTML     13K 
18: R1          Document and Entity Information                     HTML     31K 
14: R2          Balance Sheets                                      HTML     63K 
17: R3          Balance Sheets (Parenthetical)                      HTML     27K 
19: R4          Statements of Operations                            HTML     46K 
20: R5          Statement of Stockholders' Deficit                  HTML     23K 
15: R6          Statements of Cash Flows                            HTML     51K 
16: R7          Basis of Presentation                               HTML     24K 
13: R8          Economic Dependency                                 HTML     25K 
11: R9          Stock Options                                       HTML     21K 
21: R10         Income Taxes                                        HTML     56K 
22: XML         IDEA XML File -- Filing Summary                      XML     27K 
12: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS     86K 
 4: EX-101.INS  XBRL Instance -- bzyr-20111130                       XML    144K 
 6: EX-101.CAL  XBRL Calculations -- bzyr-20111130_cal               XML     51K 
 9: EX-101.DEF  XBRL Definitions -- bzyr-20111130_def                XML    111K 
 7: EX-101.LAB  XBRL Labels -- bzyr-20111130_lab                     XML    294K 
 8: EX-101.PRE  XBRL Presentations -- bzyr-20111130_pre              XML    163K 
 5: EX-101.SCH  XBRL Schema -- bzyr-20111130                         XSD     30K 
10: ZIP         XBRL Zipped Folder -- 0001104659-12-002343-xbrl      Zip     28K

‘EX-101.INS’   —   XBRL Instance — bzyr-20111130

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- Generated by Fujitsu XWand B0126 -->
<!-- Generated by IRIS Proton Version 2.0.2.4 -->
<xbrli:xbrl xmlns:bzyr="http://www.burzynskiresearch.com/20111130" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
<link:schemaRef xlink:type="simple" xlink:href="bzyr-20111130.xsd"/>
<xbrli:context id="I2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-02-28 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012Q3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2011Q3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2010-09-01 </xbrli:startDate>
<xbrli:endDate> 2010-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2012Q3YTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2011-03-01 </xbrli:startDate>
<xbrli:endDate> 2011-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2012Q3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2011-09-01 </xbrli:startDate>
<xbrli:endDate> 2011-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2012Q3YTD_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2011-03-01 </xbrli:startDate>
<xbrli:endDate> 2011-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012Q3_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2012Q3YTD_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2011-03-01 </xbrli:startDate>
<xbrli:endDate> 2011-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2011_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-02-28 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012Q3_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012Q3_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2011_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-02-28 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2011_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-02-28 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2011Q3YTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2010-03-01 </xbrli:startDate>
<xbrli:endDate> 2010-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2011Q3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2010-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2010-02-28 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:unit id="USD">
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Shares">
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USDPerShare">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<us-gaap:AdditionalPaidInCapitalCommonStock id="TAG1" decimals="0" contextRef="I2011" unitRef="USD"> 94260707 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:CommonStockSharesIssued id="TAG2" decimals="INF" contextRef="I2012Q3" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesAuthorized id="TAG3" decimals="INF" contextRef="I2011" unitRef="Shares"> 200000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare id="TAG4" decimals="INF" contextRef="I2011" unitRef="USDPerShare"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="TAG5" decimals="INF" contextRef="I2012Q3" unitRef="Shares"> 200000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare id="TAG6" decimals="INF" contextRef="I2012Q3" unitRef="USDPerShare"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockValue id="TAG7" decimals="0" contextRef="I2011" unitRef="USD"> 131449 </us-gaap:CommonStockValue>
<us-gaap:Liabilities id="TAG8" decimals="0" contextRef="I2011" unitRef="USD"> 72851 </us-gaap:Liabilities>
<us-gaap:AccruedLiabilitiesCurrent id="TAG9" decimals="0" contextRef="I2011" unitRef="USD"> 33628 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableCurrent id="TAG10" decimals="0" contextRef="I2011" unitRef="USD"> 39223 </us-gaap:AccountsPayableCurrent>
<us-gaap:Assets id="TAG11" decimals="0" contextRef="I2011" unitRef="USD"> 21596 </us-gaap:Assets>
<us-gaap:PropertyPlantAndEquipmentNet id="TAG12" decimals="0" contextRef="I2011" unitRef="USD"> 4120 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:AssetsCurrent id="TAG13" decimals="0" contextRef="I2011" unitRef="USD"> 17476 </us-gaap:AssetsCurrent>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="TAG14" decimals="0" contextRef="I2011" unitRef="USD"> 17476 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:LiabilitiesAndStockholdersEquity id="TAG15" decimals="0" contextRef="I2012Q3" unitRef="USD"> 19723 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:ResearchAndDevelopmentExpense id="TAG16" decimals="0" contextRef="D2011Q3" unitRef="USD"> 1172273 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense id="TAG17" decimals="0" contextRef="D2011Q3" unitRef="USD"> 37220 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationDepletionAndAmortization id="TAG18" decimals="0" contextRef="D2011Q3" unitRef="USD"> 180 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:OperatingExpenses id="TAG19" decimals="0" contextRef="D2011Q3" unitRef="USD"> 1209673 </us-gaap:OperatingExpenses>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="TAG20" decimals="0" contextRef="D2011Q3" unitRef="USD"> -1209673 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG21" decimals="0" contextRef="D2011Q3" unitRef="USD"> -1209673 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:EarningsPerShareBasicAndDiluted id="TAG22" decimals="2" contextRef="D2011Q3" unitRef="USDPerShare"> -0.01 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="TAG23" decimals="0" contextRef="D2011Q3" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="TAG24" decimals="0" contextRef="D2011Q3" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:ResearchAndDevelopmentExpense id="TAG25" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 4939748 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense id="TAG26" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 185623 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationDepletionAndAmortization id="TAG27" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 531 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:OperatingExpenses id="TAG28" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 5125902 </us-gaap:OperatingExpenses>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="TAG29" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -5125902 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit id="TAG30" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG31" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -5125902 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:EarningsPerShareBasicAndDiluted id="TAG32" decimals="2" contextRef="D2012Q3YTD" unitRef="USDPerShare"> -0.04 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="TAG33" decimals="0" contextRef="D2012Q3YTD" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="TAG34" decimals="0" contextRef="D2012Q3YTD" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:ResearchAndDevelopmentExpense id="TAG35" decimals="0" contextRef="D2012Q3" unitRef="USD"> 1764352 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="TAG36" decimals="0" contextRef="I2012Q3" unitRef="USD"> 18826 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:CommonStockSharesOutstanding id="TAG37" decimals="INF" contextRef="I2011" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding id="TAG38" decimals="INF" contextRef="I2012Q3" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued id="TAG39" decimals="INF" contextRef="I2011" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesIssued>
<bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses id="TAG40" decimals="0" contextRef="D2012Q3YTD_AdditionalPaidInCapitalMember" unitRef="USD"> -4762103 </bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses>
<bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses id="TAG41" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -4762103 </bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses>
<us-gaap:StockholdersEquity id="TAG42" decimals="0" contextRef="I2012Q3" unitRef="USD"> -27855 </us-gaap:StockholdersEquity>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed id="TAG43" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 387199 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<us-gaap:StockholdersEquity id="TAG44" decimals="0" contextRef="I2011" unitRef="USD"> -51255 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="TAG45" decimals="0" contextRef="I2012Q3_RetainedEarningsMember" unitRef="USD"> -99569313 </us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG46" decimals="0" contextRef="D2012Q3YTD_RetainedEarningsMember" unitRef="USD"> -5125902 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:StockholdersEquity id="TAG47" decimals="0" contextRef="I2011_RetainedEarningsMember" unitRef="USD"> -94443411 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="TAG48" decimals="0" contextRef="I2012Q3_AdditionalPaidInCapitalMember" unitRef="USD"> 99410009 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="TAG49" decimals="0" contextRef="I2012Q3_CommonStockMember" unitRef="USD"> 131449 </us-gaap:StockholdersEquity>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed id="TAG50" decimals="0" contextRef="D2012Q3YTD_AdditionalPaidInCapitalMember" unitRef="USD"> 387199 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<us-gaap:StockholdersEquity id="TAG51" decimals="0" contextRef="I2011_AdditionalPaidInCapitalMember" unitRef="USD"> 94260707 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="TAG52" decimals="0" contextRef="I2011_CommonStockMember" unitRef="USD"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="TAG53" decimals="INF" contextRef="I2011_CommonStockMember" unitRef="Shares"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding id="TAG54" decimals="INF" contextRef="I2012Q3_CommonStockMember" unitRef="Shares"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="TAG55" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> 398829 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:ProceedsFromContributedCapital id="TAG56" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> 398829 </us-gaap:ProceedsFromContributedCapital>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="TAG57" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> -399848 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:IncreaseDecreaseInAccruedLiabilities id="TAG58" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> -12 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayable id="TAG59" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> -22609 </us-gaap:IncreaseDecreaseInAccountsPayable>
<bzyr:ClinicalTrialExpensesPaid id="TAG60" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> 3411767 </bzyr:ClinicalTrialExpensesPaid>
<us-gaap:DepreciationDepletionAndAmortization id="TAG61" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> 552 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG62" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> -3789546 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="TAG63" decimals="0" contextRef="I2012Q3" unitRef="USD"> 16134 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:NetCashProvidedByUsedInContinuingOperations id="TAG64" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -1342 </us-gaap:NetCashProvidedByUsedInContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="TAG65" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 387199 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:GeneralAndAdministrativeExpense id="TAG66" decimals="0" contextRef="D2012Q3" unitRef="USD"> 75451 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationDepletionAndAmortization id="TAG67" decimals="0" contextRef="D2012Q3" unitRef="USD"> 177 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:OperatingExpenses id="TAG68" decimals="0" contextRef="D2012Q3" unitRef="USD"> 1839980 </us-gaap:OperatingExpenses>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="TAG69" decimals="0" contextRef="D2012Q3" unitRef="USD"> -1839980 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="TAG70" decimals="0" contextRef="D2012Q3" unitRef="USD"> -1839980 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:EarningsPerShareBasicAndDiluted id="TAG71" decimals="2" contextRef="D2012Q3" unitRef="USDPerShare"> -0.01 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="TAG72" decimals="0" contextRef="D2012Q3" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="TAG73" decimals="0" contextRef="D2012Q3" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:ResearchAndDevelopmentExpense id="TAG74" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> 3592998 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense id="TAG75" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> 195996 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses id="TAG76" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> 3789546 </us-gaap:OperatingExpenses>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="TAG77" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> -3789546 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:EarningsPerShareBasicAndDiluted id="TAG79" decimals="2" contextRef="D2011Q3YTD" unitRef="USDPerShare"> -0.03 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="TAG80" decimals="0" contextRef="D2011Q3YTD" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="TAG81" decimals="0" contextRef="D2011Q3YTD" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:IncomeTaxExpenseBenefit id="TAG82" decimals="0" contextRef="D2012Q3" unitRef="USD"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="TAG84" decimals="0" contextRef="I2012Q3" unitRef="USD"> -99569313 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:AdditionalPaidInCapitalCommonStock id="TAG85" decimals="0" contextRef="I2012Q3" unitRef="USD"> 99410009 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:CommonStockValue id="TAG86" decimals="0" contextRef="I2012Q3" unitRef="USD"> 131449 </us-gaap:CommonStockValue>
<us-gaap:Liabilities id="TAG87" decimals="0" contextRef="I2012Q3" unitRef="USD"> 47578 </us-gaap:Liabilities>
<us-gaap:AccruedLiabilitiesCurrent id="TAG88" decimals="0" contextRef="I2012Q3" unitRef="USD"> 43993 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableCurrent id="TAG89" decimals="0" contextRef="I2012Q3" unitRef="USD"> 3585 </us-gaap:AccountsPayableCurrent>
<us-gaap:Assets id="TAG90" decimals="0" contextRef="I2012Q3" unitRef="USD"> 19723 </us-gaap:Assets>
<us-gaap:PropertyPlantAndEquipmentNet id="TAG91" decimals="0" contextRef="I2012Q3" unitRef="USD"> 3589 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:AssetsCurrent id="TAG92" decimals="0" contextRef="I2012Q3" unitRef="USD"> 16134 </us-gaap:AssetsCurrent>
<us-gaap:CommitmentsAndContingencies id="TAG93" xsi:nil="true" contextRef="I2011" unitRef="USD"/>
<us-gaap:CommitmentsAndContingencies id="TAG94" xsi:nil="true" contextRef="I2012Q3" unitRef="USD"/>
<us-gaap:LiabilitiesAndStockholdersEquity id="TAG95" decimals="0" contextRef="I2011" unitRef="USD"> 21596 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:RetainedEarningsAccumulatedDeficit id="TAG96" decimals="0" contextRef="I2011" unitRef="USD"> -94443411 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="TAG97" decimals="0" contextRef="I2011" unitRef="USD"> 18295 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:ProceedsFromContributedCapital id="TAG98" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 387199 </us-gaap:ProceedsFromContributedCapital>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="TAG99" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -388541 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:IncreaseDecreaseInAccruedLiabilities id="TAG100" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 10365 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayable id="TAG101" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -35638 </us-gaap:IncreaseDecreaseInAccountsPayable>
<bzyr:ClinicalTrialExpensesPaid id="TAG102" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 4762103 </bzyr:ClinicalTrialExpensesPaid>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="TAG103" decimals="0" contextRef="I2011Q3" unitRef="USD"> 17103 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="TAG104" decimals="0" contextRef="I2010" unitRef="USD"> 18122 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:NetCashProvidedByUsedInContinuingOperations id="TAG105" decimals="0" contextRef="D2011Q3YTD" unitRef="USD"> -1019 </us-gaap:NetCashProvidedByUsedInContinuingOperations>
<us-gaap:IncomeTaxDisclosureTextBlock id="TAG106" contextRef="D2012Q3YTD">
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">NOTE D.      INCOME TAXES</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company follows the provisions of FASB ASC 740-10, “<i>Accounting for Uncertainty in Income Taxes.”</i>  The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company recognizes interest and penalties as interest expense when they are accrued or assessed.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The federal income tax returns of the Company for 2010, 2009, and 2008 are subject to examination by the IRS, generally for three years after they are filed.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The actual provision for income tax for the three months and nine months ended November 30, 2011 and 2010, respectively, differ from the amounts computed by applying the U.S. federal income tax rate of 34% to the pretax loss as a result of the following</font><font style="FONT-SIZE: 10pt" size="2">:</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <table style="WIDTH: 83.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in" border="0" cellspacing="0" cellpadding="0" width="83%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="64%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="31%" colspan="5"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">Three Months Ended November 30,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="64%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">2011</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.46%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">2010</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.46%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Expected income tax benefit </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(</font><font style="FONT-SIZE: 10pt" size="2">625,594</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(411,289</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Effect of expenses deducted directly by Dr. Burzynski </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">625,594</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">411,289</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Nondeductible expenses and other adjustments </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">6,018</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(26,672</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Change in valuation allowance </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(6,018</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">26,672</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">State tax</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.46%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Income tax expense</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <table style="WIDTH: 83.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in" border="0" cellspacing="0" cellpadding="0" width="83%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="64%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="31%" colspan="5"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">Nine Months Ended November 30,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="64%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">2011</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">2010</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Expected income tax benefit </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(1,742,807</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(1,288,446</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Effect of expenses deducted directly by Dr. Burzynski </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">1,742,807</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">1,288,442</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Nondeductible expenses and other adjustments </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(7,955</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(7,157</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Change in valuation allowance </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">7,955</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">7,161</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">State tax</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Income tax expense</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr></table> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">At November 30, 2011, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $365,723.  The Company’s ability to utilize net operating loss carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income.  The Company has no historical earnings on which to base an expectation of future taxable income.  Accordingly, a valuation allowance for deferred tax assets has been provided.  At November 30, 2011, the Company had net operating loss carryforwards available to offset future income in the amount of $934,925, which may be carried forward and will expire if not used between 2012 and 2032 in varying amounts</font><font style="FONT-SIZE: 10pt" size="2">.</font></p></td></tr></table>
</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="TAG107" contextRef="D2012Q3YTD">
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">NOTE C.      STOCK OPTIONS</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">At November 30, 2011, the Company had one stock-based employee compensation plan, which is described below.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35 per share, to an officer who is no longer with the Company.  </font><font style="FONT-SIZE: 10pt" size="2">The options vested as follows:</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <table style="WIDTH: 36.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.5in" border="0" cellspacing="0" cellpadding="0" width="36%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 53.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="53%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">400,000 options</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.28%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="43%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">September 14, 1996</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 53.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="53%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">100,000 options</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.28%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="43%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">June 1, 1997</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 53.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="53%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">100,000 options</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.28%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="43%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">June 1, 1998</font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The options are valid in perpetuity.  In addition, for a period of 10 years from the grant date, they increase in the same percentage of any new shares of stock issued; however, no shares were issued during such 10-year periods from the grant dates.  None of the options have been exercised as of November 30, 2011.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company follows the fair value recognition provisions of FASB ASC 718, <i>“Compensation — Stock Compensation.”</i> Under this method, compensation cost for all share-based payments is based on the grant-date fair value and amortized to expense over the requisite service period, generally the vesting period.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company did not grant any options and no options previously granted vested in any of the periods presented in these financial statements.  Due to this fact, there was no effect on net loss and loss per share.</font></p></td></tr></table>
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock id="TAG108" contextRef="D2012Q3YTD">
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">NOTE B.      ECONOMIC DEPENDENCY</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit.  Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company is economically dependent on its funding through Dr. Burzynski’s medical practice.  A portion of Dr. Burzynski’s patients are admitted and treated as part of the clinical trial programs, which are regulated by the FDA.  The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA.  These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice.  The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">It is also the intention of the directors and management to seek additional capital through the sale of securities.  The proceeds from such sales will be used to fund the Company’s operating deficit until it achieves positive operating cash flow.  There can be no assurance that the Company will be able to raise such additional capital.</font></p></td></tr></table>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="TAG109" contextRef="D2012Q3YTD">
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">NOTE A.      BASIS OF PRESENTATION</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The financial statements of Burzynski Research Institute, Inc., a Delaware corporation (the “Company”), include expenses incurred directly by S.R. Burzynski, M.D., Ph.D. (“Dr. Burzynski”) within his medical practice, related to the conduct of U.S. Food and Drug Administration (“FDA”) approved clinical trials for Antineoplaston drugs used in the treatment of cancer.  These expenses have been reported as research and development costs and as additional paid-in capital.  Cash contributions received from Dr. Burzynski have also been reported as additional paid-in capital, which are used to fund general operating expenses. Expenses related to Dr. Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements.  Dr. Burzynski is the President, Chairman of the Board and owner of over 80% of the outstanding stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons,” which he has licensed to the Company.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company and Dr. Burzynski have entered into various agreements which provide the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once an Antineoplaston drug is approved for sale by the FDA.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer.  The Company is currently conducting clinical trials on various Antineoplastons in accordance with FDA regulations. At this time, however, none of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted. In September 2004, the Company announced that the FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for the treatment of brainstem glioma.  During 2008, the FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for the treatment of all gliomas.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of November 30, 2011 and February 28, 2011, results of operations for the three and nine months ended November 30, 2011 and 2010, and cash flows for the nine months ended November 30, 2011 and 2010.  All adjustments are of a normal recurring nature.  The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year.  These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2011</font><font style="FONT-SIZE: 10pt" size="2">.</font></p></td></tr></table>
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<dei:EntityRegistrantName contextRef="D2012Q3YTD"> BURZYNSKI RESEARCH INSTITUTE INC </dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="D2012Q3YTD"> 0000724445 </dei:EntityCentralIndexKey>
<dei:DocumentType contextRef="D2012Q3YTD"> 10-Q </dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="D2012Q3YTD"> 2011-11-30 </dei:DocumentPeriodEndDate>
<dei:AmendmentFlag contextRef="D2012Q3YTD"> false </dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="D2012Q3YTD"> --02-28 </dei:CurrentFiscalYearEndDate>
<dei:EntityCurrentReportingStatus contextRef="D2012Q3YTD"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityFilerCategory contextRef="D2012Q3YTD"> Smaller Reporting Company </dei:EntityFilerCategory>
<dei:DocumentFiscalYearFocus contextRef="D2012Q3YTD"> 2012 </dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="D2012Q3YTD"> Q3 </dei:DocumentFiscalPeriodFocus>
<dei:EntityCommonStockSharesOutstanding decimals="INF" contextRef="I2012Q3" unitRef="Shares"> 131448444 </dei:EntityCommonStockSharesOutstanding>
</xbrli:xbrl>

↑Top
Filing Submission 0001104659-12-002343   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., Apr. 25, 4:59:46.1am ET